On June 2, 2025, Alphamab Oncology announced that its controlling shareholder, Rubymab Ltd., entered into a share placing agreement with Morgan Stanley & Co. International plc as the sole placing agent. The announcement did not specify the total number of shares or the price involved in the transaction. The completion of the placing is subject to certain conditions, and there is no assurance that the transaction will be finalized.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.